Sun Pharma takes Pfizer to court over Lyrica
08-04-2019
Pfizer revenues to slow as drugs lose exclusivity
31-01-2019
Pfizer secures six-month Lyrica extension in US
29-11-2018
no_limit_pictures / iStockphoto.com
US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
patent, patent expiration, Pfizer, financial filings, biopharma, generics, Lyrica
